To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
Reuters file photo Neuralink logo and Elon Musk photo are seen in this illustration taken, December 19, 2022.
Reuters
17:57 JST, January 30, 2024
Jan 29 (Reuters) – The first human patient has received an implant from brain-chip startup Neuralink on Sunday and is recovering well, the company’s billionaire founder Elon Musk said.
Initial results show promising neuron spike detection, Musk said in a post on the social media platform X on Monday.
Spikes are activity by neurons, which the National Institute of Health describes as cells that use electrical and chemical signals to send information around the brain and to the body.
The U.S. Food and Drug Administration had given the company clearance last year to conduct its first trial to test its implant on humans, a critical milestone in the startup’s ambitions to help patients overcome paralysis and a host of neurological conditions.
In September, Neuralink said it received approval for recruitment for the human trial.
The study uses a robot to surgically place a brain-computer interface (BCI) implant in a region of the brain that controls the intention to move, Neuralink said previously, adding that its initial goal is to enable people to control a computer cursor or keyboard using their thoughts alone.
The implants’ “ultra-fine” threads help transmit signals in participants’ brains, Neuralink has said.
The first product from Neuralink would be called Telepathy, Musk said in a separate post on X.
The startup’s PRIME Study is a trial for its wireless brain-computer interface to evaluate the safety of the implant and surgical robot.
Neuralink did not immediately respond to a Reuters request for further details.
The company has faced calls for scrutiny regarding its safety protocols. Reuters reported earlier this month that the company was fined for violating U.S. Department of Transportation (DOT) rules regarding the movement of hazardous materials.
The company was valued at about $5 billion last June, but four lawmakers in late November asked the U.S. Securities and Exchange Commission to investigate whether Musk had misled investors about the safety of its technology after veterinary records showed problems with the implants on monkeys included paralysis, seizures and brain swelling.
Musk wrote in a social media post on Sept. 10 that “no monkey has died as a result of a Neuralink implant.” He added that the company chose “terminal” monkeys to minimize risk to healthy ones.
